Cholecystokinin (CCK), a gastrin-like neuropeptide, exists in the central nervous system in several forms. The octapeptide (CCK-8) occurs in predominantly sulfated form (CCK-8S), and the tetrapeptide (CCK-4) occurs in smaller but significant quantities. This review highlights recent developments in preclinical and clinical research into the potential role for CCK in mediating anxiety states. Relevant animal and human studies of administration of CCK agonists are discussed, as well as recent data regarding the concentration of CCK-8S in cerebrospinal fluid from patients with panic disorder, bulimia nervosa, and obsessive compulsive disorder. Finally, the development of agents that specifically antagonize CCK receptors will be described, as will potential therapeutic uses for these new compounds. The predominant form of CCK in the CNS is the sulfated form of the octapeptide (CCK-8S), while CCK-4 exists in smaller concentrations. There are two predominant receptor subtypes for CCK: the CCK-A receptor (for "alimentary") and the CCK-B receptor (for "brain") (2). CCK-A receptors have a high affinity for CCK-SS and lesser affinity for desulfated CCK-8, CCK-4, and gastrin. The CCK-A receptors predominate in the periphery, and occur in high concentrations in the viscera as well as in the CNS (3). The CCK-B receptors, which have a high affinity for all CCK agonists, are the predominant form in the brain. The type A receptor in the CNS mediates satiety and other functions, while the B receptor appears to be important in mediating anxiety.
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The predominant form of CCK in the CNS is the sulfated form of the octapeptide (CCK-8S), while CCK-4 exists in smaller concentrations. There are two predominant receptor subtypes for CCK: the CCK-A receptor (for "alimentary") and the CCK-B receptor (for "brain") (2). CCK-A receptors have a high affinity for CCK-SS and lesser affinity for desulfated CCK-8, CCK-4, and gastrin. The CCK-A receptors predominate in the periphery, and occur in high concentrations in the viscera as well as in the CNS (3). The CCK-B receptors, which have a high affinity for all CCK agonists, are the predominant form in the brain. The type A receptor in the CNS mediates satiety and other functions, while the B receptor appears to be important in mediating anxiety.
The first description of the anxiogenic effects of CCK were reported in a study of the mechanism for satiety in sheep (4). In this study, pentagastrin was infused into administration of CCK-4 to African green monkeys (9). The behaviors elicited were consistent with fear/panic-like responses, including vigilance, agitation, restlessness, and, at peak levels of intensity of the reactions, immobility or freezing, which could be analogous to the human equivalent of panic. The response of the individual monkeys was 
C.) 
Human Cerebrospinal Fluid (CSF) Studies of CCK
On the basis of the accumulating evidence of abnormal CCK function in panic disorder, my colleagues and I examined CSF concentrations of CCK-8S in panic disorder patients and in normal comparison subjects (26). We measured CCK-85 because methods for measuring CCK-4 in CSF are not sensitive enough, but the octapeptide is present in quantities sufficiently large (i.e., ngfL) to be measured.
As can be seen in Fig. 1 , CSF concentrations of CCK-8S in panic disorder patients were lower than in normal comparison subjects. The finding of lower CSF concentrations of CCK-8S in panic disorder was thought to possibly reflect a reciprocal relationship between CCK-8 and CCK-4 in the CNS (27), and might be a reflection of increased CCK-4 activity, with a resulting reciprocal decrease in CCK-8 activity.
Alternatively 
CCK ReceptorAntagonists
In recent years, specific and highly potent antagonists for CCK receptors have been discovered and developed (31). One of the first antagonists discovered was apserlicm, a natUrally occurring benzodiazepune derived from a fungus. Subsequently, 
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CC*B Antagonists
zodiazepine-like agents have been developed that are selective for either the CCK-A or CCK-B receptor (Fig. 3) . In summary, the effects of the CNS cholecystokinin system in mediating anxiety appear to be expressed predominantly through the CCK-B receptors. The availabifity of selective antagonists for CCK receptors has allowed for initial studies to test appropriate hypotheses generated from the preclinical and clinical studies to date. New therapeutic agents may evolve from this line of research, which could significantly improve our ability to treat various psychiatric and substance abuse disorders. The next decade should provide interesting and clinically relevant information regarding the role of CCK and CCK antagonists in anxiety and in the treatment of anxiety disorders.
